IMG-004 is under clinical development by Inmagene Biopharmaceuticals and currently in Phase I for Chronic Urticaria Or Hives. According to GlobalData, Phase I drugs for Chronic Urticaria Or Hives have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMG-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMG-004 overview
IMG-004 is under development for the treatment of chronic spontaneous urticaria (CSU) and Rheumatoid arthritis. The drug candidate acts by targeting Bruton's tyrosine kinase (BTK). It is administered through oral route in the form of capsule.
It was also under development for the treatment of multiple sclerosis.
Inmagene Biopharmaceuticals overview
Inmagene Biopharmaceuticals (Inmagene) is a clinical-stage biotechnology company that develops novel therapeutics for immunological and inflammatory diseases using the QuadraTek platform. Its pipeline products include IMG-007, IMG-004, IMG-017 and IMG-008 candidates treat atopic dermatitis, alopecia areata, rheumatoid arthritis (RA), chronic spontaneous urticaria (CSU), generalized pustular psoriasis (GPP), hidradenitis suppurativa (HS), psoriatic arthritis (PsA), hidradenitis suppurativa (HS), uveitis psoriasis and ankylosing spondylitis. It also developing IMG-013 and IMG-018. The company works in partnership with pharmaceutical and biotechnology companies such as HUTCHMED and Affibody AB. ChiInmagene is headquartered in San Diego, California, the US.
For a complete picture of IMG-004’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
